Berberine HCl — Nutraceutical Grade (≥97% HPLC) & Pharma/Research Grade (≥98% HPLC) Supplier
Berberine HCl (Berberine Hydrochloride, CAS 633-65-8, berberine free base CAS 2086-83-1) — nature’s AMPK activator and the most clinically validated natural compound for metabolic health, glucose metabolism, and gut microbiome modulation. A yellow crystalline isoquinoline alkaloid sourced from Berberis aristata and Coptis chinensis with a 2500+ year history in Ayurveda and Traditional Chinese Medicine. Activates AMPK via mitochondrial complex I inhibition — the same mechanism as metformin — to drive GLUT4-mediated glucose uptake, suppress hepatic gluconeogenesis, promote Akkermansia muciniphila proliferation, and reduce LDL cholesterol. Available in nutraceutical grade (≥97% HPLC) and pharma/research grade (≥98% HPLC). ISO 9001:2015, ISO 22000, HACCP, FDA, HALAL, KOSHER, Non-GMO certified. Bulk manufacturer and wholesale supplier — premium berberine HCl powder from UPOR Biotech.
Request a QuoteProduct Overview
Berberine HCl (INCI: Berberine HCl, Berberine Hydrochloride, Berberine Chloride, Natural Yellow 18, Umbellatine, Berberinium chloride, CAS 633-65-8 HCl / CAS 2086-83-1 free base, C20H18NO4Cl, MW 371.81 g/mol HCl / 336.36 g/mol free base) is a natural isoquinoline alkaloid extracted from the roots, rhizomes, and stems of Berberis aristata (Indian barberry), Coptis chinensis (Chinese goldthread/coptis), and Hydrastis canadensis (goldenseal). With a documented medicinal history spanning over 2500 years across Ayurveda (as daruharidra/rasaut for metabolic disorders, infections, and gastrointestinal ailments) and Traditional Chinese Medicine (as huáng lián for “damp-heat” syndromes, diabetes-like wasting, and dysentery), berberine stands as one of the most extensively studied and clinically validated natural compounds in modern pharmacology. Berberine’s primary and defining mechanism is AMPK (AMP-activated protein kinase) activation — the cellular “metabolic master switch” that governs whole-body energy homeostasis. Berberine inhibits mitochondrial respiratory chain complex I (NADH:ubiquinone oxidoreductase), reducing ATP production and consequently increasing the AMP/ATP ratio. This energetic stress signal triggers AMPK phosphorylation (Thr172 of the alpha-subunit), initiating a coordinated metabolic program: (1) GLUT4 translocation — AMPK phosphorylates AS160/TBC1D4, releasing the GLUT4 retention signal and enabling glucose transporter translocation to the plasma membrane in skeletal muscle and adipose tissue, driving insulin-independent glucose uptake; (2) PGC-1alpha upregulation — AMPK-mediated PGC-1alpha activation promotes mitochondrial biogenesis and oxidative metabolism, improving cellular energy efficiency; (3) Hepatic gluconeogenesis suppression — AMPK phosphorylates and degrades CREB co-activator CRTC2 and downregulates PEPCK and glucose-6-phosphatase (G6Pase) transcription, reducing hepatic glucose output — a mechanism directly paralleling metformin’s action; (4) Lipogenesis inhibition — AMPK phosphorylates and inactivates acetyl-CoA carboxylase (ACC) and HMG-CoA reductase, simultaneously reducing fatty acid synthesis and cholesterol biosynthesis. Beyond AMPK, berberine exerts profound gut microbiome modulation: berberine selectively promotes the proliferation of Akkermansia muciniphila — a keystone mucin-degrading bacterium whose abundance inversely correlates with obesity, insulin resistance, and metabolic endotoxemia — and increases beneficial Bifidobacterium and Lactobacillus populations. This microbiome remodeling enhances short-chain fatty acid (SCFA) production — butyrate (colonocyte fuel, HDAC inhibitor, GPR109A agonist), acetate (substrate for hepatic lipogenesis regulation), and propionate (intestinal gluconeogenesis activator, GPR41/43 signaling) — which collectively reinforce metabolic benefits through gut-brain axis, incretin secretion (GLP-1/PYY), and systemic anti-inflammatory signaling. Berberine also upregulates intestinal tight junction proteins (occludin, ZO-1, claudin-1) reducing gut permeability and lipopolysaccharide (LPS) translocation — addressing the low-grade metabolic endotoxemia that underlies obesity-associated insulin resistance. The HCl salt form (berberine hydrochloride) is the preferred form for supplementation: it crystallizes as a stable yellow alkaloid salt with defined stoichiometry, improved aqueous solubility relative to the free base, and is the form used in virtually all clinical trials. Key purity markers include total berberine content (≥97% on dried basis for nutraceutical grade; ≥98% for pharma/research grade) with a tight related alkaloids profile (palmatine, coptisine, jatrorrhizine, epiberberine) confirming botanical authenticity via characteristic isoquinoline alkaloid fingerprint ratios.
As a leading berberine HCl manufacturer and bulk supplier, UPOR Biotech provides high-purity berberine hydrochloride powder for nutraceutical brands, dietary supplement manufacturers, pharmaceutical companies, contract manufacturers, and private-label formulators worldwide. Berberine’s positioning at the intersection of metabolic health, natural glucose management, and gut microbiome science aligns with three of the strongest consumer health megatrends — the global GLP-1 and weight management market (where berberine’s AMPK-driven metabolic benefits complement and may augment GLP-1 pathway effects via SCFA-stimulated L-cell GLP-1 secretion), the natural alternative to metformin positioning (the most searched natural compound for glucose support), and the gut health revolution (berberine’s unique microbiome-modulating properties distinguish it from every other metabolic health ingredient). With a projected CAGR exceeding 8% for the global berberine market through 2030, driven by rising metabolic syndrome prevalence, consumer preference for plant-derived alternatives to synthetic pharmaceuticals, and expanding clinical evidence, berberine HCl represents a strategic portfolio ingredient for supplement brands. OEM and private label formulations available with flexible MOQ starting at 1 kg. Free sample available for qualified B2B buyers. Every shipment includes full documentation: COA, MSDS, HPLC chromatogram, botanical source certification, and stability data.
Berberine vs Metformin vs Inositol — Metabolic Health Compared: Why Berberine Is Nature’s AMPK Activator
Comparing the three leading evidence-based metabolic health interventions reveals complementary mechanisms and distinct clinical positioning. Metformin is the first-line pharmaceutical for type 2 diabetes — a mitochondrial complex I inhibitor that activates AMPK, suppresses hepatic gluconeogenesis, and improves insulin sensitivity. A landmark 2008 head-to-head RCT demonstrated that berberine 500 mg 3x daily produced comparable HbA1c reduction to metformin 500 mg 3x daily in type 2 diabetes patients over 13 weeks (Yin et al., Metabolism). Berberine matches metformin’s AMPK activation mechanism but adds three unique advantages metformin lacks: (1) significant LDL cholesterol reduction via hepatic LDL receptor upregulation — a well-replicated finding across multiple meta-analyses averaging 0.5-0.7 mmol/L LDL-C reduction, (2) gut microbiome remodeling — selective Akkermansia muciniphila and Bifidobacterium proliferation with enhanced SCFA production, and (3) 2500-year traditional medicine safety record with lower reported gastrointestinal side effects when properly dosed. Inositol (myo-inositol and D-chiro-inositol, typically in a 40:1 ratio) operates through a fundamentally different mechanism — insulin second-messenger signaling via IP3/DAG pathway — and is most clinically validated for PCOS-related insulin resistance and ovulatory function. Inositol and berberine are complementary, not competitive: inositol addresses the ovarian insulin-signaling defect in PCOS, while berberine addresses systemic AMPK-driven metabolic dysfunction. Emerging evidence suggests potential synergy when combined. Berberine’s defining differentiator: it is the only natural compound with a mechanism directly mirroring metformin’s AMPK activation pathway, plus additional LDL-lowering and microbiome-modulating activities — making it the most comprehensive single-ingredient natural metabolic health active available. For supplement formulators, berberine HCl offers the rare combination of pharmaceutical-class mechanism, robust clinical evidence (50+ RCTs), natural plant origin, and established consumer awareness.
Technical Specifications
| Property | Specification |
|---|---|
| Product Name | Berberine HCl — Nutraceutical Grade (≥97% HPLC) / Pharma & Research Grade (≥98% HPLC) |
| INCI Name | Berberine HCl |
| Common Name / Synonyms | Berberine Hydrochloride; Berberine Chloride; Natural Yellow 18; Umbellatine; Berberinium chloride; Coptis chinensis extract; Berberis aristata extract |
| CAS Number (HCl Salt) | 633-65-8 |
| CAS Number (Free Base) | 2086-83-1 |
| Molecular Formula (HCl) | C20H18NO4Cl (C20H18NO4Cl) |
| Molecular Formula (Free Base) | C20H18NO4 (C20H19NO5 for the hydroxide form) |
| Molecular Weight (HCl) | 371.81 g/mol |
| Molecular Weight (Free Base) | 336.36 g/mol |
| Botanical Source | Berberis aristata (Indian barberry) / Coptis chinensis (Chinese goldthread/coptis) — natural plant isoquinoline alkaloid |
| Key Mechanism | AMPK activator via mitochondrial complex I inhibition → increased AMP/ATP ratio → GLUT4 translocation + PGC-1alpha activation + hepatic gluconeogenesis suppression. Gut microbiome modulation (Akkermansia muciniphila proliferation, SCFA production). Hepatic LDL receptor upregulation. |
| Appearance | Yellow to golden-yellow crystalline powder with characteristic alkaloid odor |
| Assay — Nutraceutical Grade | ≥97.0% Berberine HCl (HPLC, on dried basis) |
| Assay — Pharma / Research Grade | ≥98.0% Berberine HCl (HPLC, on dried basis) |
| Berberine Content (as Free Base) | ≥87.0% berberine free base equivalent (calculated from berberine HCl assay, on dried basis) |
| Related Alkaloids Profile | Palmatine ≤3.0%, Coptisine ≤2.0%, Jatrorrhizine ≤1.5%, Epiberberine ≤1.0% (HPLC area normalization). Total related alkaloids ≤5.0%. Characteristic isoquinoline fingerprint confirms Berberis/Coptis botanical authenticity. |
| Identification | IR spectrum conforms to berberine chloride reference standard (USP/EP); HPLC retention time matches berberine chloride RS; UV-Vis lambda-max at 228, 264, 345, 420 nm in methanol |
| Loss on Drying | ≤2.0% (105°C, 3 hours) |
| Residue on Ignition | ≤0.2% (sulfated ash) |
| pH (0.1% Aqueous Solution) | 4.5 – 6.5 |
| Solubility | Sparingly soluble in water (~2 mg/mL at 25°C as HCl salt); soluble in hot water and ethanol; practically insoluble in chloroform and ether. Solubility improves under acidic conditions (pH below 4). |
| Melting Point | Approximately 205°C (decomposition, as chloride salt) |
| Heavy Metals (Total) | ≤10 ppm (as Pb) |
| Elemental Impurities | Pb ≤2 ppm; As ≤1 ppm; Hg ≤1 ppm; Cd ≤1 ppm (USP <232> / ICH Q3D compliant) |
| Microbial Limits | TAMC ≤1000 CFU/g; TYMC ≤100 CFU/g (USP <61> / EP <2.6.12>); Pathogens (E. coli, Salmonella, S. aureus, P. aeruginosa) — Absent in 10 g (USP <62> / EP <2.6.13>) |
| Residual Solvents | USP <467> / EP <5.4> / ICH Q3C Class 3 compliant; Ethanol ≤5000 ppm; Methanol ≤3000 ppm |
| Recommended Dosage | 500 mg 2–3 times daily (1000–1500 mg/day total), 30 minutes before meals. Divided dosing recommended due to ~3–4 hour elimination half-life. |
| Grade / Standards | Nutraceutical Grade (≥97% HPLC) / Pharma & Research Grade (≥98% HPLC); USP/EP monograph reference standards available |
| Certifications | ISO 9001:2015, ISO 22000, HACCP, FDA Facility Registration, HALAL, KOSHER, Non-GMO, BSE/TSE-Free |
| Packaging | 1 kg / 5 kg / 10 kg sealed aluminum foil bags with PE liner (light-protective); 25 kg fiber drums with double PE liner and light-protective outer bag (yellow alkaloid — protect from light) |
| Storage | 15 – 25°C, tightly sealed in original light-protective container, protect from light, moisture, and excessive heat |
| Shelf Life | 3 years from date of manufacture under recommended storage conditions in unopened original container |
Key Benefits — Berberine HCl
AMPK Activation — Nature’s Metabolic Master Switch, Comparable to Metformin
Berberine inhibits mitochondrial complex I, increasing the AMP/ATP ratio and triggering AMPK phosphorylation — the same mechanism as metformin. AMPK activation drives GLUT4-mediated glucose uptake, suppresses hepatic gluconeogenesis (PEPCK/G6Pase downregulation), and promotes mitochondrial biogenesis via PGC-1alpha. A landmark 2008 RCT demonstrated comparable HbA1c reduction to metformin at 500 mg 3x daily.
AMPK ActivatorGlucose Metabolism — Insulin-Independent GLUT4 Translocation & Hepatic Regulation
Berberine promotes GLUT4 translocation to the plasma membrane in muscle and adipose tissue independently of insulin signaling. Suppresses hepatic glucose output via PEPCK and G6Pase downregulation. Inhibits intestinal alpha-glucosidase, delaying carbohydrate absorption. These complementary mechanisms provide comprehensive multi-target glucose management from a single natural compound.
Glucose MetabolismGut Microbiome Modulation — Akkermansia Proliferation & SCFA Production
Berberine selectively promotes Akkermansia muciniphila proliferation — a keystone bacterium inversely correlated with obesity and insulin resistance. Increases beneficial Bifidobacterium and Lactobacillus populations while enhancing SCFA production (butyrate, acetate, propionate). Upregulates tight junction proteins (occludin, ZO-1) for improved gut barrier integrity and reduced metabolic endotoxemia.
Gut MicrobiomeLDL Cholesterol Reduction — Hepatic LDL Receptor Upregulation & Cardiovascular Support
Berberine upregulates hepatic LDL receptor expression via an AMPK-dependent, statin-independent mechanism — increasing LDL clearance from circulation. Meta-analyses consistently report 0.5–0.7 mmol/L LDL-C reduction. Combined with AMPK-mediated HMG-CoA reductase phosphorylation and triglyceride-lowering effects, berberine provides comprehensive cardiovascular-metabolic protection.
LDL ReductionApplications
Metabolic Health & Glucose Management Dietary Supplements
Berberine HCl at 500 mg per capsule, 2–3x daily for glucose metabolism, insulin sensitivity, and metabolic syndrome support — the most clinically validated natural AMPK activator for dietary supplement formulations.
Weight Management & GLP-1 Support Nutraceutical Formulations
Berberine HCl combined with GLP-1-supporting ingredients for comprehensive weight management — AMPK activation + SCFA-stimulated endogenous GLP-1 secretion + gut microbiome remodeling for metabolic health.
Cardiovascular Health — Cholesterol & Lipid Management Supplements
Berberine HCl at 500 mg 2–3x daily for natural LDL cholesterol reduction via hepatic LDL receptor upregulation — a statin-independent mechanism supported by multiple meta-analyses. OEM formulations for heart health product lines.
Gut Health & Microbiome Support Probiotic-Adjuvant Formulations
Berberine HCl paired with probiotics and prebiotics for gut health formulations targeting Akkermansia muciniphila and Bifidobacterium proliferation, SCFA production, and intestinal barrier integrity.
Ayurvedic & TCM Traditional Medicine Extract Standardization
Standardized berberine HCl as the bioactive marker compound for Berberis aristata (daruharidra) and Coptis chinensis (huáng lián) extract formulations — bridging 2500-year traditional medicine systems with modern HPLC quantification and quality standards.
Pharma & Clinical Research Grade Investigational Formulations
Pharma/research grade berberine HCl (≥98% HPLC) for clinical trials, university research programs, and pharmaceutical development — supported by 50+ published RCTs across metabolic, cardiovascular, and gut health endpoints.
Frequently Asked Questions
Berberine HCl (CAS 633-65-8, berberine free base CAS 2086-83-1) is a natural isoquinoline alkaloid extracted from Berberis aristata (barberry), Coptis chinensis (coptis/goldthread), and Hydrastis canadensis (goldenseal). With a 2500+ year history in Ayurveda and Traditional Chinese Medicine, berberine is one of the most extensively studied natural compounds for metabolic health. Its primary mechanism is AMPK (AMP-activated protein kinase) activation — the cellular “metabolic master switch” that regulates energy homeostasis. Berberine inhibits mitochondrial complex I of the electron transport chain, reducing ATP production and increasing the AMP/ATP ratio. This energetic stress signal activates AMPK, which then: (1) triggers GLUT4 translocation for insulin-independent glucose uptake, (2) upregulates PGC-1alpha for mitochondrial biogenesis, (3) suppresses hepatic gluconeogenesis via PEPCK/G6Pase downregulation — directly paralleling metformin’s mechanism, and (4) enhances fatty acid oxidation while inhibiting lipogenesis. Beyond AMPK, berberine promotes Akkermansia muciniphila proliferation and enhances SCFA production in the gut microbiome. The HCl salt form provides superior stability and is the form used in virtually all clinical trials. UPOR Biotech provides both nutraceutical (≥97% HPLC) and pharma/research (≥98% HPLC) grades.
Berberine HCl provides a dual benefit profile targeting both metabolic and gut health pathways. For glucose metabolism: AMPK-mediated GLUT4 translocation increases glucose uptake in skeletal muscle and adipose tissue independently of insulin signaling; mitochondrial complex I inhibition reduces hepatic gluconeogenesis via PEPCK/G6Pase downregulation; intestinal alpha-glucosidase inhibition delays carbohydrate absorption; and AMPK-driven suppression of mTOR/S6K1 improves insulin sensitivity at the IRS-1 level. For gut health: berberine promotes Akkermansia muciniphila proliferation — a keystone bacterium associated with improved metabolic health and gut barrier integrity; increases beneficial Bifidobacterium and Lactobacillus populations; enhances short-chain fatty acid (SCFA) production including butyrate (colonocyte fuel, HDAC inhibitor), acetate, and propionate (intestinal gluconeogenesis activator, GPR41/43 signaling); and reduces gut permeability via upregulation of tight junction proteins (occludin, ZO-1, claudin-1), lowering metabolic endotoxemia. Additional benefits include LDL cholesterol reduction via hepatic LDL receptor upregulation (0.5–0.7 mmol/L average reduction in meta-analyses) and modulation of bile acid metabolism via FXR signaling. This multi-pathway profile — AMPK activation + microbiome remodeling + LDL reduction — makes berberine the most comprehensive single-ingredient natural metabolic health active available.
Standard dosage: 500 mg berberine HCl taken 2–3 times daily (total 1000–1500 mg/day), administered 30 minutes before meals for optimal postprandial glucose management. Divided dosing is essential because berberine has a short elimination half-life (~3–4 hours). The primary formulation challenge is berberine’s low oral bioavailability (~5%) due to extensive first-pass P-glycoprotein (P-gp) efflux in the intestinal epithelium and rapid hepatic metabolism via CYP2D6 and CYP3A4. Proven bioavailability enhancement strategies include: (1) co-administration with piperine (from black pepper, 5–10 mg per dose) — can increase berberine absorption by up to 2000% in preclinical models via P-gp and CYP3A4 inhibition, (2) dihydroberberine — the reduced form with approximately 5x greater bioavailability than standard berberine HCl, (3) liposomal or phytosomal encapsulation technologies, (4) nano-emulsion and solid lipid nanoparticle delivery systems, and (5) co-administration with sodium caprate or other permeation enhancers. UPOR Biotech supplies berberine HCl as the hydrochloride salt — the most commonly used and extensively studied form — and can support customers developing advanced delivery systems. For supplement formulators, starting with standard berberine HCl and incorporating piperine or exploring dihydroberberine/encapsulation technologies provides a clear bioavailability innovation roadmap.
Berberine and metformin share a remarkably similar mechanism of action — both are mitochondrial complex I inhibitors that activate AMPK, reduce hepatic gluconeogenesis, and improve insulin sensitivity. A landmark 2008 head-to-head RCT (Yin et al., Metabolism) demonstrated that berberine 500 mg 3x daily produced comparable HbA1c reduction to metformin 500 mg 3x daily in type 2 diabetes patients over 13 weeks. Key comparisons: vs. Metformin — berberine provides additional LDL cholesterol reduction (via hepatic LDL receptor upregulation, averaging 0.5–0.7 mmol/L) and gut microbiome modulation (Akkermansia/Bifidobacterium proliferation and SCFA production) not observed with metformin, but has lower bioavailability requiring 3x daily dosing. vs. Inositol (myo-inositol/D-chiro-inositol) — inositols work through insulin second-messenger signaling (IP3/DAG pathway) primarily addressing PCOS-related insulin resistance at the ovarian level; berberine works systemically through AMPK activation. These two are complementary, not competitive, and emerging evidence suggests potential synergy when combined. vs. Chromium — chromium is a micronutrient cofactor for insulin signaling with modest effect sizes; berberine is a direct pharmacological AMPK activator with effect sizes comparable to metformin. Berberine’s unique advantage: AMPK activation + gut microbiome modulation + LDL cholesterol reduction — all from a single natural plant alkaloid with 2500-year safety history and 50+ published RCTs.
Every shipment includes: COA (HPLC purity ≥97.0% nutraceutical or ≥98.0% pharma/research grade, full impurity profile including palmatine/coptisine/jatrorrhizine related alkaloids, heavy metals ≤10 ppm with Pb ≤2 ppm / As ≤1 ppm / Hg ≤1 ppm / Cd ≤1 ppm, residual solvents per USP <467> / ICH Q3C, microbial panel per USP <61>/<62>), MSDS, HPLC Chromatogram (signed and dated, with characteristic isoquinoline alkaloid fingerprint), Botanical Source Certification (Berberis aristata / Coptis chinensis species authentication with geographic origin), Heavy Metal Analysis Report, BSE/TSE-Free Statement, Non-GMO Statement, Allergen Statement, HALAL Certificate, KOSHER Certificate, ISO 22000 + HACCP, ISO 9001:2015, FDA Facility Registration, Stability Data (25°C/60%RH real-time 36-month and 40°C/75%RH accelerated 6-month, with photostability data for this light-sensitive yellow alkaloid), and Complete Lot Traceability from botanical raw material to finished product. Free sample available for qualified B2B buyers. MOQ: 1 kg. All documents provided in English.